Schrodinger launches Bunsen AI co-scientist, raises 2026 drug discovery revenue outlook
The company reported second-quarter ACV growth of 27% and lifted its full-year drug discovery revenue guidance after an Ajax Therapeutics milestone payment.
Schrödinger, Inc. reported financial results for the quarter ended June 30, 2026 on August 5, 2026, alongside the launch of an early access version of a new agentic AI tool called Bunsen for molecular discovery.
The company described Bunsen as built to run Schrödinger's validated, physics-based computational platform for planning and executing complex molecular discovery workflows and interpreting the results, unlike general-purpose AI agents1. Schrödinger said Bunsen lets computational chemists handle concurrent research sessions across more programs and also opens up advanced computational methods to drug hunters without a computational chemistry background.1 To support the expected rise in usage from Bunsen, Schrödinger's longtime partners NVIDIA and Google Cloud will supply a combined AI platform and infrastructure, including access to the NVIDIA BioNeMo Agent Toolkit, for early customers.1
On the commercial side, Schrödinger announced a strategic software agreement with Bristol Myers Squibb to deploy Bunsen, expanding the company's platform footprint within BMS's research organization.1 Separately, Schrödinger entered a global drug discovery and development collaboration with Simcere Pharmaceutical Group, under which Schrödinger will lead drug design and optimization during a joint research phase while Simcere leads later preclinical and clinical development, with Schrödinger eligible for milestone payments and tiered royalties on sales.1
On guidance, Schrödinger raised its expected 2026 drug discovery revenue to a range of $65 million to $75 million, up from a prior range of $55 million to $65 million, citing a $10 million collaboration milestone tied to the Ajax Therapeutics acquisition.1 Total-year ACV guidance was reaffirmed at $218 million to $228 million, representing 10-15% growth over 2025.1
On cash, Schrödinger held $418.8 million in cash, cash equivalents, restricted cash and marketable securities1 as of the quarter's end.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.